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Abstract. TRIO and F-actin-binding protein (TrioBP), 
which was initially discovered as a binding partner of Trio 
and F-actin, is a critical factor associated with hearing 
loss in humans. However, the function of TrioBP in cancer 
has not been investigated. In the present study, TrioBP 
expression was indicated to be highly elevated in U87-MG 
and U343-MG cells. Furthermore, the TrioBP mRNA 
expression level was markedly increased in U87-MG and 
U251-MG cells compared with that in cerebral cortex cells, 
as determined by deep sequencing. Comprehensive analysis 
of a public TCGA dataset confirmed that TrioBP expression 
is elevated in patients with glioblastoma. In summary, the 
present data indicate that TrioBP expression is increased 
in glioblastoma cell lines and in patients with glioma, 
suggesting that TrioBP has potential as a diagnostic marker 
or therapeutic agent for glioma.
Introduction
Gliomas, including glioblastoma multiforme (GBM), have a 
poor prognosis and high rate of relapse (1). The most common 
type of glial neoplasm is astrocytic tumor, approximately 80% 
of which are glioblastomas with common genetic defects (2). 
Gliomas can be treated by open surgery, chemotherapy, and/or 
radiotherapy. However, no effective treatments are available, 
resulting in a mean survival duration of <15 months (3).
Angiogenesis is a common feature of cancer and is mediated 
by upregulation of angiogenic genes (4). Angiogenesis leads to 
the development of large twisting vessels (5). The disordered 
vasculature of GBM leads to a diminished blood supply, 
which reduces the effectiveness of chemotherapy and radio-
therapy (6). Anti-angiogenic approaches reportedly enhance 
the efficacy of chemotherapeutics (7). Bevacizumab (BEV), 
a recombinant protein that inhibits VEGF-A, is a promising 
candidate anti-angiogenesis drug (8). The efficacy of BEV 
cotreatment for GBM patients with temozolomide (TMZ) and 
radio/chemotherapy has been studied (9). A clinical study of 
avastin (AVAglio) in GBM patients indicated that cotreatment 
with BEV and avastin improved the progression-free survival 
duration (PFS, 4.4 months) while radiotherapy with BEV 
cotreatment showed no significant benefit for survival (10). 
Therefore, there is an urgent need to develop drugs other than 
TMZ and anti-VEGF agents for GBM patients.
TRIO and F‑actin‑binding protein (TrioBP) was identified 
as a novel Trio-interacting protein by screening of a skeletal 
muscle cDNA library (11). TrioBP contains an N-terminal 
pleckstrin homology domain and a C-terminal coiled-coil 
region. The interaction of TrioBP-1 with F-actin stabilizes the 
structure of the latter (11). Subsequent studies of the structure 
of TrioBP genes revealed that the TrioBP-4 and TrioBP-5 
isoforms are required for hearing (12,13). Linkage analysis 
of families has identified several mutations in the 22q13 
region designated DFNB28, which spans 34 genes, including 
TrioBP-1 (14). TrioBP-1 is ubiquitously expressed, whereas 
TrioBP-4 and TrioBP-5 are expressed mainly in the eye 
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and ear. Mutations in TrioBP-4 and TrioBP-5 have been linked 
to a form of autosomal recessive nonsyndromic deafness. All 
of the TrioBP mutations in DFNB28 that result in deafness 
are located in exon 6 of TrioBP and affect only the TrioBP-4 
and TrioBP-5 isoforms (15). Because the siRNA-induced 
decrease in Trio expression inhibits the migration of glioblas-
toma cells (16), TrioBP, as a Trio-interacting protein, might be 
involved in the development of gliomas. Therefore, the role of 
TrioBP in glioblastoma was evaluated to enable the develop-
ment of novel chemotherapeutics. Taken together, our results 
indicate that TrioBP has potential as a candidate therapeutic 
agent for glioblastoma. An enhanced understanding of the 
role of TrioBP in glioblastoma should provide important 
information for the management of cancer.
Materials and methods
Antibodies and reagents. Anti-TrioBP antibodies were 
purchased from Novus Biologicals, LLC (Littleton, CO, USA) 
and anti-actin antibodies were from Sigma-Aldrich (Merck 
KGaA, Darmstadt, Germany). Horseradish peroxidase-conju-
gated anti-mouse IgG or anti-rabbit IgG secondary antibodies 
were purchased from Komabiotech (Seoul, Korea). The siRNA 
against human TrioBP were synthesized by Intergrated DNA 
technologies. The siRNA sequences for TrioBP were the 
following; 5'-TCC CAG CAG AAC CAT CCA ACA AGA GAA-3'.
Cell culture and transfection. The glioblastoma cells 
(U87, U25, and U343-MG) were maintained in medium 
(RPMI) supplemented with 10% FBS, 25 mM HEPES 
(Thermo Fisher Scientific, Inc., Waltham, MA, USA), 1% 
Antibiotics-Antimycotics (Thermo Fisher Scientific, Inc.). U87 
and U251-MG cells were transiently transfected with 30 nM 
control siRNA or TrioBP siRNA by using Neon Transfection 
System (Thermo Fisher Scientific, Inc.).
Patient samples. The study was approved by the Hospital 
Institutional Review Board (approval number CNUH 
2013-11-006) according to the Declaration of Helsinki at 
Chungnam National University Hospital (Daejeon, Korea), 
and written informed consent was obtained from each patient 
before surgery. Normal brain tissue samples were obtained 
from cadavers alternatively, from autopsy of surrounding 
normal brain of glioblastoma patient who underwent surgery.
Immunoblot analysis. The immunoblot analysis was 
performed as the described previously (17,18). Briefly, cells 
were placed on ice and extracted with lysis buffer containing 
50 mM Tris-HCl, pH 7.5, 1% v/v Nonidet P-40, 120 mM 
NaCl, 25 mM sodium fluoride, 40 mM β-glycerol phosphate, 
0.1 mM sodium orthovanadate, 1 mM phenylmethylsulfonyl 
fluoride, 1 mM benzamidine, and 2 µM microcystin-LR. 
Lysates were centrifuged for 15 min at 12,000 x g. The cell 
extracts were resolved by 10-15% SDS-PAGE, and transferred 
to Immobilon-P membranes (EMD Millipore, Billerica, MA, 
USA). The filters were blocked for 1 h in 1X Tri-buffered saline 
buffer (TBS; 140 mM NaCl, 2.7 mM KCl, 250 mM Tris-HCl, 
pH 7.4), containing 5% skimmed milk and 0.2% Tween-20, 
followed by an overnight incubation with the anti-TrioBP and 
anti‑actin antibodies diluted 1,000‑fold at 4˚C. The secondary 
antibody was horseradish peroxidase-conjugated anti-mouse 
IgG or anti-rabbit IgG (Koma Biotech, Seoul, Korea), diluted 
5,000-fold in the blocking buffer. The detection of protein 
expression was visualized by enhanced chemiluminescence, 
according to the manufacturer's instructions (Thermo Fisher 
Scientific, Inc.).
Reverse transcription‑quantitative reverse transcription‑poly‑
merase chain reaction (RT‑qPCR). Total RNA was extracted 
from frozen tissue samples or from cells using the PureHelix 
RNA Extraction Solution (Nanohelix, South Korea). The 
cDNA was synthesized from total RNA with the SuperScript 
III First-Strand Synthesis System for RT-qPCR (Invitrogen; 
Thermo Fisher Scientific, Inc.). The RT-qPCR measurement 
of individual cDNAs was performed using SYBR-Green dye 
to measure duplex DNA formation with the StepOne Plus 
real-time PCR system (Invitrogen; Thermo Fisher Scientific, 
Inc.) and normalized to the expression of glyceraldehyde 
3-phosphate dehydrogenase (GAPDH) RNA. The following 
primers were used in the RT-qPCR (forward, reverse); human 
TrioBP: F-5'-TCC AAG GTC TCC CTT AGT ACA/R-5'-GTG 
GGA CTG GAC TTG CTA; human GAPDH: F-5'-TCG ACA 
GTC AGC CGC ATC TTC TTT/R-5'-TAC GAC CAA ATC CGT 
TGA CTC CGA.
RNA sequencing and RNA‑Seq data analysis. Total RNA of 
U87-MG, U251-MG and normal brain was extracted using 
TRIzol reagent (Invitrogen) following the manufacturer's 
procedures. The total RNA quantity and purity were analysis 
of Bioanalyzer 2100 and RNA 6000 Nano LabChip Kit 
(Agilent Technologies, Inc., Santa Clara, CA, USA). Roughly 
10 µg of total RNA was subjected to isolate Poly (A) mRNA 
with poly-T oligo attached magnetic beads (Invitrogen; 
Thermo Fisher Scientific, Inc.). Following purification, the 
mRNA is fragmented into small pieces using divalent cations 
under raised temperature. Then the cleaved RNA fragments 
were reverse‑transcribed to create the final cDNA library in 
accordance with the protocol for the mRNA-Seq sample prep-
aration kit (Illumina, Inc., San Diego, CA, USA). The average 
insert size for the paired-end libraries was 300 bp (± 50 bp). 
Next we performed the paired-end sequencing on an Illumina 
Hiseq 2000 system at Macrogen (Seoul, Korea) following the 
vendor's recommended protocol. For each sample, sequenced 
reads were aligned to the UCSC human reference genome (19) 
using the Tophat package (20), which initially removes a 
portion of the reads based on quality information accom-
panying each read and then maps the reads to the reference 
genome. FPKM (fragments per kilobase of exon per million 
fragments mapped) were calculated to compare the expression 
level of TrioBP mRNA variants in each sample.
Confocal imaging analysis and indirect immunofluorescence. 
U251-MG cells were grown on glass coverslips until they were 
50‑70% confluent. After 24 h, the cells were fixed in 4% parafor-
maldehyde at room temperature for 10 min and permeabilized 
in 0.2% Triton X-100 for 5 min at room temperature. Then 
cells were incubated in blocking buffer containing 5% bovine 
serum albumin (Sigma-Aldrich; Merck KGaA) in 1X TBS 
for 1 h at 37˚C. The rabbit polyclonal anti‑TrioBP was diluted 
200-fold for primary antibody and incubated for overnight. 
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The secondary antibody, FITC-conjugated anti-rabbit anti-
body (BD Biosciences, Franklin Lakes, NJ, USA) was used. 
After appropriate rinsing, cover slips were mounted with 
Vectashield (Vector Laboratories, Inc., Burlingame, CA, USA) 
and visualized using a Zeiss confocal microscope (Zeiss AG, 
Oberkochen, Germany).
Immunohistochemistry. The analysis of immunohistochem-
istry was performed as the described previously (21). A human 
cancer tissue array slide with paraffin sections was purchased 
from Bio Max (US Biomax Inc; Thermo Fisher Scientific, Inc.). 
Histostain-Plus kits (Zymed Laboratories Inc., San Francisco, 
CA, US) were used in accordance with the manufacturer's 
instructions for the immunohistochemistry of tissue array. 
Briefly, paraffin sections were deparaffinized with xylene 
and rehydrated in a graded series of ethanol. The slide was 
submerged in peroxidase quenching solution for 10 min. After 
it was washed twice with PBS for 5 min, it was added with 2 
drops of Reagent A for blocking and incubated for 30 min. 
Following two washes with PBS, the primary antibody was 
Figure 1. Changes of TrioBP expression in human brain tumors. (A) Human 
glioma tissue arrays were analyzed by immunohistochemistry (IHC) for 
TrioBP staining. Representative images from two patients were shown. Scale 
bars, 100 µm. (B) Total cell lysates from normal and GBM tissues (tumors 
no. 1 and 2) from patients were analyzed for TrioBP expression (top panel). 
Tumor-associated normal tissue served as a control (Tumor Asso.). Relative 
densities were calculated by densitometry. Relative differences in TrioBP 
expression levels were determined by normalizing all densitometric values to 
those of actin (in each lane) and setting the control values to 1 (bottom panel). 
The results are presented as means ± SDs of data from two independent 
experiments. *P<0.05, **P<0.01.
Figure 2. Expression of TrioBP in glioblastoma cell lines. (A) For immuno-blot 
analysis with anti-TrioBP and anti-actin antibodies, cell lysates were isolated 
from 4 established GBM cell lines (U87-MG, U251-MG, and U343-MG) and 
one established non-cancerous cell line (293A). The results are representative 
of 3-independent experiments (top panel). Relative density was obtained by 
densitometry of the corresponding immunoblot data. Relative and statistical 
differences of TrioBP expression were determined by normalizing values for 
actin in each lane and set the values for 293A as 1 (bottom panel). The results 
are presented as means ± SD. of three independent experiments. Statistical 
analysis was performed using one-way ANOVA followed by Tukey's post 
hoc test (*P<0.05, **P<0.01 vs. 293A). (B) Extracted total RNA from each 
GBM cell line was analyzed using human TrioBP specific primer sets by 
real-time quantitative reverse transcription-polymerase chain reaction 
(RT-qPCR), as described in the Materials and Methods section. The results 
are presented as means ± SD of three independent experiments. Statistical 
analysis was performed using one-way ANOVA followed by Tukey's post hoc 
test (***P<0.001 vs. 293A).
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applied at 4˚C for overnight. Then biotinylated secondary 
antibody, Reagent B, was added after rinsing with PBS. It was 
incubated at room temperature for 1 h. It was rinsed with PBS 
and dropped with enzyme conjugated Reagent C. After it was 
washed with PBS, DAB chromogen, and a mixture of Reagent 
D1, D2, and D3, it was dropped, and signals were observed with 
a florescence microscope. Then the reaction was stopped with 
distilled water, and pictures were taken with a microscope.
Bioinformatics data set. Glioma data sets and corresponding 
clinical data were downloaded from the publicly avail-
able databases (213 cases from the TCGA GBM dataset 
(http://www.betastasis.com/glioma/tcga_gbm/)). Normal; 
n=11, Classical; n=54, Mesenchy-mal; n=58, Neural; n=33, 
Proneural; n=57.
Real‑time assay for cell proliferation and migration. 
Real-time assay for cell proliferation and migration were 
measured using an xCELLigence RTCA DP system (Roche 
Diagnostics, Indianapolis, IN, USA), which monitors cellular 
events in real-time without the incorporation of labels. Briefly, 
cells were placed into well of an E-plate 16 (for proliferation; 
U87-MG 2x104, U251-MG 1.2x104 cells) or Matrigel-coating 
(Matrigel: serum free media, 1:40) of the upper chamber 
of CIM-plate 16 (for migration; U87-MG 2x104, U251-MG 
1.2x104 cells) and incubated for indicated times.
Statistical analysis. Data are expressed as the mean ± SD from 
at least three separate experiments performed triplicate. The 
differences between groups were analyzed using a Student's 
t-test and P<0.05 was considered significant, and P<0.01 
was highly significant compared with corresponding control 
values. Statistical analyses were carried out using SPSS soft-
ware ver. 13.0 (SPSS, Inc., Chicago, IL, USA). Other statistical 
analysis performed using analysis of variance (ANOVA) and 
Tukey's post hoc tests, using the GraphPad Prism 5 software 
(GraphPad Software, Inc., La Jolla, CA, USA). Differences 
were considered significant if P<0.05, P<0.01, and P<0.001.
Results
TrioBP expression is high in glioblastoma tissue. 
Immunohistochemical (IHC) analysis using a tissue array and 
anti-TrioBP antibody showed stronger signals in brain tumor 
tissues than in surrounding normal tissues (Fig. 1A). Total 
lysates of normal and cancerous tissues from GBM patients 
were subjected to immunoblotting using an anti-TrioBP anti-
body. TrioBP levels in GBM tissues were higher than those 
in the surrounding normal tissues (Fig. 1B), suggesting that 
TrioBP expression is upregulated in glioblastoma patients.
TrioBP expression is elevated in glioblastoma cell lines. Based 
on the high TrioBP expression in samples from GBM patients 
(Fig. 1), TrioBP expression in glioblastoma cell lines was 
assessed by immunoblotting. TrioBP expression was signifi-
cantly increased in U87-MG and U343-MG cells than in the 
other cell lines (Fig. 2A). Reverse transcription-quantitative 
polymerase chain reaction (RT-qPCR) showed that the mRNA 
level of TrioBP was increased in U343-MG, and U87-MG cells 
compared with that in the controls (Fig. 2B).
Upregulation of TrioBP mRNA in U251‑MG and U87‑MG 
cells. As TrioBP expression was elevated in glioblastoma cells 
(Fig. 2A and B), the TrioBP mRNA levels in glioblastoma 
cell lines were determined by transcriptome profiling. Total 
RNA was prepared from U251-MG (low TrioBP expression) 
and U87-MG (high TrioBP expression) glioblastoma cells. 
Next, mRNA was split into small fragments to produce a 
cDNA library. The number of fragments per kilobase of 
exon per million fragments mapped (FPKM) was consid-
ered to be representative of the TrioBP mRNA level. FPKM 
values were greater in U87-MG cells (34.98) and U251-MG 
Figure 3. Relative changes of TrioBP transcripts from GBM cells in standard RNA-seq data. Total RNA were isolated from two GBM cell lines (U87-MG 
and U251-MG) and normal brain tissue. These samples were further analyzed by the standard RNA deep sequencing (RNA-seq) as described in the material 
and methods. RNA-seq read density for TrioBP transcripts was plotted with the relative RNA-seq read coverage (counts). Fragments per kilobase of exon per 
million fragments mapped (FPKM) were calculated to compare the expression level of TrioBP mRNA variants in each sample.
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cells (27.58) than in cerebral cortex cells (11.87) (Fig. 3), 
demonstrating that TrioBP transcription is enhanced in 
glioblastoma cells.
TrioBP knockdown suppresses the proliferation and migra‑
tion of U251‑MG and U87‑MG cells. To investigate the roles 
of TrioBP in cancer cells, U251-MG and U87-MG cells were 
transfected with TrioBP siRNA and their proliferation and 
migration were evaluated by Excelligence. TrioBP expres-
sion was significantly reduced (Fig. 4A). siRNA-mediated 
knockdown of TrioBP inhibited the proliferation of 
U87-MG cells (left) and U251-MG cells (right) (Fig. 4B). 
The reduction in proliferation of U87-MG cells (left) was 
greater than that of U251-MG cells (right). In addition, the 
migration of U87-MG and U251-MG cells was suppressed 
(Fig. 4C). Therefore, TrioBP may play important roles in 
cancer cells.
Cytoplasmic localization of TrioBP in U251‑MG cells. To 
investigate further its roles in GBM cells, the intracellular 
localization of TrioBP in U251-MG cells was evaluated. 
Interestingly, TrioBP was distributed in a punctate pattern, 
possibly associated with the cytoskeleton and cytosol (Fig. 5), 
indicating that localization to the cytosol is important for its 
function in glioblastoma cells.
Bioinformatic analysis of the TCGA GBM cohort. A bioin-
formatic analysis was performed on the TCGA GBM cohort. 
Figure 4. Effects of TiroBP on cell proliferation and migration in GBM cells. (A) U87 and U251-MG cells were transiently transfected with control-siRNA 
(siRNA) or TrioBP-siRNA (siTrioBP). After 72 h -transfection, cell lysates were analyzed by western blotting with anti-TrioBP antibodies and anti-β-actin 
antibodies. (B) The proliferation of knockdowned cells were measured using an xCELLigence system in U87-MG cells (left panel) or U251-MG cells (right 
panel) for 150 h. Values are the means ± SEM (n=4; **P<0.01). (C) The migration of knockdown cells were measured by an xCELLigence RTCA DP system 
in U87-MG cells (left panel) and U251-MG cells (right panel) for 72 h. These results are representative of three independent experiments (*P<0.05, **P<0.01).
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Similar to the above results, TrioBP expression was increased 
in classical (n=54), mesenchymal (n=58), neural (n=33), and 
proneural (n=57) glioblastomas compared with the level 
in normal controls (n=11; one-way analysis of variance, 
P<0.0001; Fig. 6).
Discussion
GBM is an aggressive type of brain tumor with a poor prog-
nosis despite the use of multiple therapies. Molecular targeting 
may facilitate the development of effective treatment strate-
gies for GBM (1). Therefore, novel biomarkers and candidate 
therapeutics for glioblastomas are urgently needed.
In this study, TrioBP was found to have potential as a marker 
of GBM, as its expression was elevated in a GBM cell line and 
samples from GBM patients. Each of nine mutations in TrioBP 
leads to hearing loss, from prelingual severe to profound nonsyn-
dromic deafness (12,13). TrioBP interacts with Trio, which has 
rho guanine nucleotide exchange factor (GEF) activity due to 
its kinase domain (11), resulting in inhibition of the function 
of Trio in cell adhesion (22). RhoGEFs, downstream effectors 
of Rho GTPases, stimulate the invasiveness and survival of 
glioma cells (23). TrioBP-1 also interacts with F-actin, leading 
to the stabilization of F-actin structures (11). The characteris-
tics of its binding partners (Trio and F-actin) (23,24) suggest 
a role for TrioBP in tumorigenesis. However, the function of 
TrioBP in glioblastoma had not been investigated. Therefore, 
we determined whether TrioBP participates in the progres-
sion of brain tumors, including GBM. Unexpectedly, TrioBP 
expression was high in glioblastoma tissue (Fig. 1A). This 
was confirmed by immunoblotting of total cell lysates from 
normal and cancerous tissues from GBM patients sampled 
during surgery (Fig. 1B). TrioBP expression was also high in 
U87-MG and U343-MG cells (Fig. 2A). RT-qPCR analysis 
revealed that TrioBP mRNA levels are elevated in U343-MG, 
and U87-MG cells (Fig. 2B) compared with that in 293A cells. 
Furthermore, the FPKM of TrioBP mRNA level was elevated 
in U251-MG and U87-MG cells compared with that in normal 
brain cells (Fig. 3). TrioBP‑specific siRNA in human mesen-
chymal stem cells suppresses cell proliferation and migration 
by decreasing F-actin levels (25). Moreover, TrioBP isoforms 4 
and 5 reportedly promote the motility of pancreatic cancer 
cells (26). Indeed, the proliferation and migration (which are 
characteristics of GBM cells) of TrioBP-knockdown U87-MG 
and U251-MG cells were also inhibited (Fig. 4).
To investigate further its roles in GBM, the intracellular local-
ization of TrioBP in U251-MG cells was evaluated. Interestingly, 
TrioBP was distributed in a punctate pattern, possibly associated 
with the cytoskeleton and cytosol (Fig. 5), indicating that local-
ization to the cytosol is important for its function in glioblastoma 
cells. A bioinformatic analysis of the TCGA GBM cohort showed 
that TrioBP expression was high in all GBMs tested (Fig. 6), 
suggesting that TrioBP expression is correlated with the clinical 
parameters of gliomas. In conclusion, TrioBP is related to glio-
blastoma and may have potential for predicting the prognosis of 
glioblastoma patients.
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